Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas

Journal of Investigative Dermatology

Volumn 124, Issue 4, 2005, Pages 741-750

  Ni, Xiao ^a,b   Zhang, Chunlei ^a   Talpur, Rakhashandra ^a   Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Activation induced cell death; Apoptosis; Cutaneous T cell lymphoma; Fas; Fas ligand

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; CASE REPORT; CELL DEATH; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL LINE; LYMPHOCYTE; MALE; PATHOGENESIS; PRIORITY JOURNAL; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION;

EID: 16844371989     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23657.x     Document Type: Article

References (49)

1. Abrahams VM, Kamsteeg M, Mor G: The Fas/Fas ligand system and cancer: Immune privilege and apoptosis. Mol Biotechnol 25:19-30, 2003
2. Bernengo MG, Novelli M, Quaglino P, et al: The relevance of the CD4+ CD26-subset in the identification of circulating Sézary cells. Br J Dermatol 144:125-135, 2001
3. Bossi G, Griffiths GM: Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med 5:90-96, 1999
4. Carbonari M, Tedesco T, Del Porto P, Paganelli R, Fiorilli M: Human T cells with a type-2 cytokine profile are resistant to apoptosis induced by primary activation: Consequences for immunopathogenesis. Clin Exp Immunol 120:454-562, 2000
5. De Panfilis G: 'Activation-induced cell death': A special program able to preserve the homeostasis of the skin? Exp Dermatol 11:1-11, 2002
6. Dereure O, Levi E, Vonderheid EC, Kadin ME: Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: A possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol 118:949-956, 2002
7. Dereure O, Portales P, Clot J, Guilhou JJ: Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol 143:1205-1210, 2000
8. Dirsch VM, Stuppner H, Vollmar AM: Helenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of Bcl-x (L) or Bcl-2. Cancer Res 61:5817-5823, 2001
9. El-Khatib M, Stanger BZ, Dogan H, Cui H, Ju ST: The molecular mechanism of FasL-mediated cytotoxicity by CD4+ Th1 clones. Cell Immunol 163:237-244, 1995
10. Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnette B: Cutting edge: The tumor counterattack hypothesis revisited: Colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 164:5023-5027, 2000
11. Green DR, Droin N, Pinkoski M: Activation-induced cell death in T cells. Immunol Rev 193:70-81, 2003
12. Green DR, Ferguson TA: The role of fas ligand in immune privilege. Nat Rev Mol Cell Biol 2:917-924, 2001
13. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192, 1995
14. Heald P, Rook A, Perez M, et al: Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 27:427-433, 1992
15. Heald P, Van SL, Edelson R: Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 130:198-203, 1994
16. Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M: Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood 101:2132-2136, 2003
17. Jackow CM, Gather JC, Hearne V, Asano AT, Musser JM, Duvic M: Association of erythrodermic cutaneous T cell lymphoma, superantigen-positive staphylococcus aureus, and oligoclonal T-cell receptor Vb gene expansion. Blood 89:32-40, 1997
18. Kayagaki N, Kawasaki A, Ebata T, et al: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182:1777-1783, 1995
19. Kim YH, Chow S, Varghese A, Hoppe RT: Clinical Characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides. Arch Dermatol 135:26-32, 1999
20. Lenardo MJ: The molecular regulation of lymphocyte apoptosis. Semin Immunol 9:1-5, 1997
21. Li JH, Rosen D, Sondel P, Berke G: Immune privilege and FasL: Two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology 105:267-277, 2002
22. Li-Weber M, Krammer PH: The death of a T-cell: Expression of the CD95 ligand. Cell Death Differ 9:101-103, 2002
23. Lowin B, Mattman C, Hahne M, Tschopp J: Comparison of Fas(Apo-1/CD95)-and perforin-mediated cytotoxicity in primary T lymphocytes. Int Immunol 8:57-63, 1996
24. Maher S, Toomey D, Condron C, Bouchier-Hayes D: Activation-induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumor counterattack. Immunol Cell Biol 80:131-137, 2002
25. Matzinger P: The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 145:185-192, 1991
26. Meech SJ, Edelson R, Walsh P, Morris DA, Duke RC: Reversible resistance to apoptosis in cutaneous T cell lymphoma. Ann NY Acad Sci 941:46-58, 2001
27. Nagata S, Golstein P: The Fas death factor. Science 267:1449-1456, 1995
28. Nguyen T, Russell J: The regulation of FasL expression during activation-induced cell death (AICD). Immunology 103:426-434, 2001
29. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M: Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: A potential mechanism of tumor immune escape? Clin Cancer Res 7:2682-2692, 2001
30. Oberg HH, Lengl-Janssen B, Kabelitz D, Janssen O: Activation-induced T cell death: Resistance or susceptibility correlate with cell surface fas ligand expression and T helper phenotype. Cell Immunol 181:93-100, 1997
31. O'Connell J, O'Sullivan GC, Collins JK, Shanahan: The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expression Fas ligand. J Exp Med 184:1075-1082, 1996
32. Salih HR, Starling GC, Brandi SF, et al: Differentiation of promyelocytic leukaemia: Alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression. Br J Haematol 117:76-85, 2002
33. Smith D, Sieg S, Kaplan D: Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol 160:4159-4160, 1998
34. Strauss G, Knape I, Melzner I, Debatin KM: Constitutive caspase activation and impaired death-inducing signaling complex formation in CD95-resistant, long-term activated, antigen-specific T cells. J Immunol 171:1172-1182, 2003
35. Suda T, Okazaki T, Naito Y, et al: Expression of the Fas ligand in cells of T cell lineage. J. Immunol 154:3806-3813, 1995
36. Talpur R, Duvic M: A typical lymphoid infiltration occurring at the site of a healed varicella zoster infection. Clin Lymphoma 3:253-256, 2003
37. Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD: Mycosis fungoides - a disease of antigen persistence. Br J Dermatol 91:607-616, 1974
38. Thestrup PK, Kaltoft K: Genotraumatic T cells and cutaneous T-cell lymphoma. A causal relationship? Arch Dermatol Res 11:97-101, 1994
39. Tokura Y, Yagi J, O'Malley M, Lewis JM, Takigawa M, Edelson RL, Tigelaar RE: Superantigenic Staphylococcal exotoxins induce T-cell proliferation in the presence of langerhans cells or class II bearing keratinocytes and stimulate keratinocytes to produce T-cell activating cytokines. J Invest Dermatol 102:31-38, 1994
40. Varadhachary AS, Perdow SN, Hu C, Ramanarayanan M, Salgame P: Differential ability of T cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci USA 94:5778-5783, 1997
41. Villunger A, Egle A, Marschitz I, et al: Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood 90:12-20, 1997
42. Vowels BR, Cassin M, Vonderheid EC, Rook AH: Aberrant cytokine production by Sézary syndrome patients: Cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 99:90-94, 1992
43. Vowels BR, Lessin SR, Cassin M, Jaworsky C, Benoit B, Wolfe JT, Rook AH: Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 103:669-673, 1994
44. Wang JK, Zhu B, Ju ST, Tschopp J, Marshak-Rothstein A: CD4+ T cells reactivated with superantigen are both more sensitive to FasL-mediated killing and express a higher level of FasL Cell Immunol 179:153-164, 1997
45. Washington LT, Huh YO, Powers LC, Duvic M, Jones D: A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol 2:5, 2002
46. Webb SD, Sherratt JA, Fish RG: Cells behaving badly: A theoretical model for the Fas/FasL system in tumour immunology. Math Biosci 179:113-129, 2002
47. Weinstock MA, Horm JW: Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 260:42-46, 1988
48. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. Clin Cancer Res 8:1234-1240, 2002
49. Zoi-Toli O, Vermeer MH, De Vries E, Van Beek P, Meijer CJ, Willemze R: Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): Association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 143:313-319, 2000